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Interferon alpha (IFNα) is approved for adjuvant treatment of stage III melanoma in Europe
and the US. Its clinical efficacy, however, is restricted to a subpopulation of patients while
side effects occur in most of treated patients.Thus, the identification of predictive biomark-
ers would be highly beneficial to improve the benefit to risk ratio. In this regard, STAT3
is important for signaling of the IFNα receptor. Moreover, the STAT3 single-nucleotide
polymorphism (SNP) rs4796793 has recently been reported to be associated with IFNα
sensitivity in metastatic renal cell carcinoma. To translate this notion to melanoma, we
scrutinized the impact of rs4796793 functionally and clinically in this cancer. Interestingly,
melanoma cells carrying the minor allele of rs4796793 were the most sensitive to IFNα
in vitro. However, we did not detect a correlation between SNP genotype and STAT3 mRNA
expression for either melanoma cells or for peripheral blood lymphocytes. Next, we ana-
lyzed the impact of rs4796793 on the clinical outcome of 259 stage III melanoma patients
of which one-third had received adjuvant IFNα treatment. These analyses did not reveal a
significant association between the STAT3 rs4796793 SNP and patients’ progression free
or overall survival when IFNα treated and untreated patients were compared. In conclusion,
STAT3 rs4796793 SNP is no predictive marker for the efficacy of adjuvant IFNα treatment
in melanoma patients.
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INTRODUCTION
Malignant melanoma is an aggressive skin cancer originating
from melanocytes. Due to the continuously raising incidence
of melanoma among the Caucasian population, it represents an
increasing health problem. Indeed, in the US, melanoma is one of
the few common cancers with increasing incidence rates over the
last decade, i.e., a 2.4% increase per year among white women and
2.1% among white men during 1999–2009 (1). A total of 68,130
new cases of melanoma, and 8,700 patients dying from melanoma
had been predicted for 2010 in the US (2). Moreover, the eco-
nomic burden of this disease is also reflected by the recent report
that an individual in the US loses on average 20.4 years of their
potential lifetime as a result of melanoma mortality compared
with 16.6 years for all other malignant cancers (3).
The prognosis of a melanoma patient is largely dependent on
the stage of disease. While early-stage melanoma can be cured
in most cases by surgical excision of the tumor, already for
patients with loco-regional disease beyond the primary tumor the
Abbreviations: IFNα, interferon alpha; PBL, peripheral blood lymphocytes; STAT3,
signal transducer and activator of transcription 3; SNP, single-nucleotide polymor-
phism.
prognosis is highly impaired. Among patients with nodal metas-
tases, the 5-year survival rates were 78, 59, and 40% for patients
with stage IIIA, IIIB, and IIIC melanoma, respectively. The sub-
grouping is based on primary tumor characteristics, ulceration
of the primary tumor, loco-regional spreading, and number of
affected lymph nodes (4). This impaired prognosis is despite the
initial curative attempt of radical surgery to remove the primary
tumor and loco-regional metastases (4).
Based on the high risk of relapse of stage III melanoma patients,
which by surgical interventions are rendered to no evidence of
disease (NED), adjuvant therapy would be indicated. The only
currently approved adjuvant therapy – despite a recently reported
positive clinical trial for adjuvant ipilimumab therapy of stage III
melanoma – is interferon-α (IFNα). In 1995, high-dose IFNα-
2b, and in 2011, pegylated IFNα-2b has been approved by the
FDA for melanoma patients who are at high risk of recurrence.
However, the percentage of patients indeed benefiting from adju-
vant IFNα therapy is limited. Consequently, ever since the first
reports demonstrating anti-tumor effects of IFNα for melanoma
(5), several studies have been conducted to identify the opti-
mal therapeutic schedule and the benefiting patient subpopula-
tion. Meta-analyses of these trials demonstrated that IFNα has a
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consistent effect on relapse-free survival but no or only marginal
effect on overall survival (OS), which had been attributed to the
fact that only a subpopulation of patients benefit from treatment.
A recent meta-analysis of two EORTC trials confirmed that lim-
ited tumor burden in stage III and ulceration of the primary tumor
were the only predictive factors for adjuvant IFNα therapy (6).
Recent observations in other cancers suggest that the effi-
cacy of IFNα therapy depends on the genetic predisposition.
A screen of 463 single nucleotide polymorphisms (SNPs) in 33
candidate genes in metastatic renal cell carcinoma patients receiv-
ing IFNα therapy demonstrated a significant association of the
signal transducer and activator of transcription 3 (STAT3) SNP
rs4796793 with clinical response (7). STAT3 is an integral mol-
ecule of the IFNα receptor signaling (8) and the rs4796793 SNP
correlated with STAT3 mRNA expression (7). This SNP is located
in the 5′ region of the gene, 1633 bp upstream of the ATG site.
In addition, in a murine melanoma model, blockade of STAT3
enhanced the therapeutic efficacy of IFN-alpha immunotherapy
(9). These observations prompted us to scrutinize the impact
of rs4796793 on the therapeutic efficacy of adjuvant IFNα in
melanoma. Here, we report that despite the fact that there was
no correlation between STAT3 mRNA expression and genotype,
melanoma cells carrying the minor allele were more sensitive to
IFNα in vitro. However, this notion did not translate into the
clinical situation as the STAT3 rs4796793 genotype did not cor-
relate with the outcome of adjuvant IFNα treatment in stage III
melanoma.
PATIENTS AND METHODS
GENOTYPING
TaqMan allelic discrimination assay for SNP rs4796793 genotyp-
ing was purchased from Applied Biosystems (C27977213; Foster
City, CA, USA). Polymerase chain reaction (PCR) was performed
according to the manufactures instructions in 20µl volume reac-
tions with 1µl DNA on a 7500 Fast Real time PCR system (Applied
Biosystems).
QUANTITATIVE RT-PCR ANALYSES FOR STAT3
Endogeneous STAT3 levels were determined for 35 peripheral
blood lymphocytes (PBL) samples as well as 18 melanoma cell
lines by real time PCR analyses in TaqMan technology using the
comparative ∆∆CT method. PBL samples were obtained from
melanoma patients who did not receive therapy at the time point
the blood was drawn. Total RNA was isolated from approximately
3× 106 cells. Samples of total RNA were subjected to reverse tran-
scription. Primers and probe for STAT3 were designed with Primer
Express software (Applied Biosystems,Weiterstadt, Germany). The
assay (sense 5´-GGG CAC AAA CAC AAA AGT GAT G; antisense
5´-CAG CTC CTC AGT CAC AAT CAG G; probe 5´-FAM-AGA
ATT CAA ACA CTT GAC CCT GAG GGA GCA) detects all three
STAT3 mRNA transcript variants. GAPDH (Applied Biosystems)
served as endogenous control. The relative expression levels of
STAT3 normalized to GAPDH and relative to the PBL sample
pat1 heterozygote for the SNP was calculated as 2∆∆CT with
∆∆CT= (CT STAT3, sample – CT GAPDH, sample) – (CT STAT3, pat1 –
CT GAPDH, pat1). CT is defined as the cycle when the threshold
level of fluorescence is reached.
CELL CULTURE
Eleven melanoma cell lines were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum. Four of these had the
CC genotype (BLM, M19, M26, MelJuso), three the both genotype
(FM79, FM82, Mel2A), and the remaining four the GG genotype
(SkMel28, MaMel60, MaMel71, Mel888).
MTS ASSAY
In order to determine the impact of IFNα on melanoma cells, the
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4 sulfophenyl)-2H-tetrazolium] cell proliferation assay
(Promega) was used according to the manufactures instruc-
tions. MTS is a tetrazolium reagent that is reduced by metabol-
ically active cells. Melanoma cell lines were cultivated in trip-
licates in 96 well plates at 1000 (BLM, FM82, M26, Mel2A,
Mel888,MelJuso,SKmel28),4000 (FM79,M19,MaMel60),or 8000
(MaMel71) cells per well with normal medium or supplemented
with 51,200 U/ml IFNα for 4 days. Extinction at 490 nm and back-
ground at 650 nm were measured with the SpectrostarNano (BMG
Labtech, Ortenberg, Germany). First, with the blank corrected
extinctions, the growth of the cells compared to the basal meta-
bolic rate determined on day 1 before addition of IFNα was
calculated. The inhibitory effect of IFN was then determined by
(growthmedium control − growthIFNα)/growthmedium control*100.
PATIENTS
Serum from advanced melanoma patients from frozen serum
banks hosted by Skin Cancer Unit, Mannheim and the Department
of Dermatology, Würzburg served as DNA source for genotyp-
ing as previously described (10). In order to be included into
the study, the following criteria had to be fulfilled: (i) patients
with histologically confirmed melanoma, (ii) a stage III diag-
nosis with a minimum follow-up of 2 months, (iii) Caucasian
origin, and (iv) extended information available on their med-
ical history including whether patients received adjuvant IFN
therapy after stage III diagnosis. Patients with secondary malig-
nancies were excluded from the study. Detailed patient charac-
teristics are given in Table 1. The collection of sera and clinical
data were performed after patients’ informed consent with Insti-
tutional Review Board approval. The presented work was con-
ducted according to the principles expressed in the Declaration of
Helsinki.
STATISTICAL METHODS
Statistical analysis was performed with Prism (GraphPad La Jolla,
CA, USA) or Stata 11.2 (StataCorp LP, College Station, TX, USA).
For univariate analyses, the Kaplan–Meier method was used to
compare survival time between groups. Differences of survival
time were assessed by the log-rank test. IFNα sensitivity or STAT3
expression of the different groups were compared by one-way
ANOVA parametric when the data passed normality testing or
else non-parametric, i.e., Kruskal–Wallis with Dunn’s post tests.
Univariate as well as multivariate analyses Cox’s proportional-
hazard regression model were applied when the models had
passed the proportional-hazard assumption based on Schoenfeld
residuals.
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Table 1 | Patient characteristics.
All No adjuvant
therapy
Adjuvant IFNα
therapy
Gender
F 119 (46.0%) 82 (44.8%) 37 (48.7%)
M 140 (54.1%) 101 (55.2%) 39 (51.3%)
Median age at
diagnosis [IQR]
54.3 [41.4–64.7] 56.7 [43–65.5] 48.9 [35.9–61.6]
Histological type
ALM 26 (10.0%) 20 (10.9%) 6 (7.9%)
LMM 5 (1.9%) 5 (2.7%) 0
NM 94 (36.3%) 66 (36.1%) 28 (36.8%)
SSM 70 (27.0%) 49 (26.8%) 21 (27.6%)
Other 7 (2.7%) 5 (2.7%) 2 (2.6%)
Non-classifiable 7 (2.7%) 7 (3.8%) 0
Unknown 50 (19.3%) 31 (16.9%) 19 (25.0%)
Ulceration pT
yes 57 (22.0%) 43 (23.5%) 14 (18.4%)
no 109 (42.1%) 80 (43.7%) 29 (38.2%)
unknown 93 (35.9%) 60 (32.8%) 33 (43.4%)
STAT3 rs4796793
CC 135 (52.1%) 99 (54.1%) 36 (47.4%)
Both 102 (39.4%) 68 (37.2%) 34 (44.7%)
GG 22 (8.5%) 16 (8.7%) 6 (7.9%)
ALM, acral-lentiginuous melanoma; LMM, lentigo maligna melanoma; IQR, inter-
quartile range; NM, nodular melanoma; SSM, superficial spreading melanoma.
RESULTS
STAT3 rs4796793 GENOTYPE’S IMPACT ON STAT3 mRNA EXPRESSION
AND IFNα SENSITIVITY
It has been previously reported that the STAT3 rs4796793 geno-
type correlates with endogenous STAT3 expression in lymphocytes
(7). To test the relevance of this observation in melanoma, par-
ticular in melanoma patients, we genotyped PBL and melanoma
cell lines for STAT3 rs4796793 SNP and subsequently measured
the STAT3 mRNA expression these. As expected from the role of
STAT3 for lymphocytes, its expression was significantly higher in
PBLs than in the melanoma cell lines (p< 0.0001; Kruskal–Wallis).
However, within the two cell types, we could not detect a relevant
difference of expression based on the SNP genotype (Figure 1A).
Nevertheless, we next established if the STAT3 rs4796793 was
associated with IFNα sensitivity of melanoma cell lines. This
analysis revealed a clear trend toward an increased IFNα sensi-
tivity of melanoma cell lines with a homozygote STAT3 rs4796793
minor allele. Indeed, the IFNα sensitivity increased from homozy-
gote major allele to heterozygote and to homozygote with minor
allele. This difference, however, was statistically not significant
(p= 0.1259, Kruskal–Wallis; Figure 1B).
STAT3 rs4796793 GENOTYPE’S IMPACT ON THE CLINICAL COURSE OF
MELANOMA
Two patient cohorts, i.e., with or without adjuvant IFNα therapy,
were included to be able to distinguish if STAT3 rs4796793 SNP is
a predictive or a mere prognostic biomarker. Of the 259 patients,
who were included, all had been diagnosed with or progressed to
stage III melanoma. One hundred nineteen were female (46%) and
140 male (54.1%). The median age at diagnosis of stage III was
56.5 years. The median follow-up time from stage III diagnosis was
38.9 months; within this follow-up time, 159 patients developed
distant metastases and 136 deaths were observed. About one-third
(n= 76) of the patients had received IFNα as adjuvant therapy in
stage III. Follow-up times for patients with or without adjuvant
IFNα therapy were similar, but the treated cohort was significantly
younger both at initial diagnosis or at progression to stage III
(p= 0.008). Information on presence of absence of ulceration was
available for 64.1% of the patients, i.e., 22% with, 42.1% without,
and 35.9% with unknown ulceration status; these subpopulations
were equally distributed among the two cohorts. Detailed patient
and tumor characteristics and the genotypic frequencies of the
STAT3 rs4796793 SNP are given in Table 1. From all patients, the
genotype could be determined. The observed genotype frequen-
cies are similar to the frequencies reported for Europeans on the
SNP database websites of the National Center for Biotechnology
Information (dbSNP, http://www.ncbi.nlm.nih.gov/snp/) ranging
from 54.2 to 58.3% for CC, 33.6 to 39% for CG, and 3.3 to 8.8%
for GG.
Since therapeutic efficacy of adjuvant IFNα therapy is most
evident in delay of disease progression, we analyzed the impact of
rs4796793 on distant metastasis free survival (DMFS). For both
the no-adjuvant-therapy group as well as the IFNα−adjuvant-
therapy group, Kaplan–Meier analyses did not reveal any signif-
icant association between STAT3 rs4796793 SNP genotype and
DMFS (Figures 2A,B; p= 0.2053 or p= 0.9423, respectively; log-
rank test). Despite the observation that the SNP genotype had
no influence on DMFS in our patient groups, we tested for
a potential effect of the STAT3 rs4796793 SNP genotype on
OS by the Kaplan–Meier method. Again, the rs4796793 geno-
type had no impact on survival for patients receiving IFNα
adjuvant therapy or not (p= 0.8403 or p= 0.7061, respectively;
log-rank test; Figures 2C,D). It should be further noticed
that when we performed multivariate Cox regression analy-
ses to adjust for gender and age at diagnosis of stage III, the
SNP genotype still was not associated with the risk of pro-
gression. This was also the case when ulceration of the pri-
mary tumor was included in the analyses, but this informa-
tion was available only for 64.1% of our patients reducing the
size of the patient groups for analysis accordingly (data not
shown).
DISCUSSION
Melanoma is regarded as one of the most lethal skin cancers. This
is still true, despite major breakthroughs in melanoma research
resulting in new therapies, such as small molecule kinase inhibitors
or immune checkpoint blocking antibodies, which have been
proven to be both effective and beneficial in advanced melanoma
patients (11). Nevertheless, most patients responding to kinase
inhibitors develop resistance to these and at best half of the patients
respond to checkpoint blocking antibodies; thus, there is still an
indication for adjuvant therapy for high-risk melanoma patients
to avoid progression to metastatic disease. The only approved
adjuvant therapeutic to date is IFNα. Unfortunately, a recent meta-
analysis of 14 randomized clinical trials could neither identify
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FIGURE 1 | STAT3 rs4796793 dependent endogeneous STAT3 mRNA
expression and IFNα sensitivity. (A) STAT3 mRNA expression was
measured by real-time PCR in peripheral blood lymphocytes (PBL) and
melanoma cell lines (MM). A CG genotype PBL sample served as
calibrator. ANOVA analyses did not show significant differences (PBL,
p=0.0863, Kruskal–Wallis; MM, p= 0.3127, parametric). (B) MM lines
were subjected to 51200 IU IFNα/ml or not, after 4 days their metabolic
activity was measured by MTS assay. Depicted are the means with
standard error for each cell line measured in at least two independent
experiments.
FIGURE 2 | STAT3 SNP rs4796793 does not influence distant metastasis
free survival (DMFS) nor overall survival (OS) in stage III melanoma
patients. Patients were stratified according to their rs4796793 SNP.
Kaplan–Meier plots for DMFS or OS of melanoma patients without (A,C) or with
adjuvant IFNα therapy (B,D) in stage III. Below each graph, the patient numbers
(pts.) at risk are given. Log-rank test was performed for statistical analysis.
an optimal IFNα dose and/or treatment duration nor the subset
of patients benefiting from therapy (12). The latter is of par-
ticular importance as adjuvant IFNα therapy is associated with
substantial toxicity in most of the patients (13). Consequently, a
predictive biomarker would improve the risk (=toxicity) to ben-
efit (=reduced risk of relapse/progression) ratio. In this regard, a
recent meta-analysis of two EORTC trials demonstrated that only
ulceration of the primary tumor and tumor stage are possible
predictive factors for adjuvant IFNα (6).
Clinical efficacy of a therapeutic intervention, however, does
not only dependent on tumor characteristics, but is also influenced
by the patients’ genetics, which is particularly true for immune
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modulating therapies, such as IFNα (14). Notably, the effects of
type I IFNs on the adaptive immune system are tightly regulated
(15). One of the integral molecules of the IFN receptor signaling is
STAT3 (8) and a SNP in STAT3 (i.e., rs4796793) has been reported
to be associated with response to IFNα therapy in renal cell carci-
noma patients (7). SNPs associated with response to therapy may
affect the response either directly or indirectly by being in link-
age disequilibrium with other disease-modulating alleles. In the
case of rs4796793 and the effect of IFNα in renal cell carcinoma,
it is assumed to be a direct effect, since the authors reported a
small (R2= 0.14) but significant correlation between rs4796793
and STAT3 mRNA expression in Epstein–Barr virus transformed
B-lymphocyte cell lines, i.e., a higher expression in cells being
homozygote for the major allele (7). The increased endogeneous
expression of STAT3 mRNA in cell lines harboring the major allele
of rs4796793 was explained by increased binding of NKX2-5 to
the STAT3 promoter, since this genotype contains an additional
NKX2-5 binding site. Here, however, we did not observe a sig-
nificant difference in endogeneous STAT3 mRNA for PBLs or for
melanoma cell lines depending on the STAT3 rs4796793 geno-
type. These cell types may lack the respective transcription factor
network, i.e., NKX2-5 and the antagonizing transcription factors
NR2F1 and HMX1, or other transcription factors might be more
relevant for endogenous STAT3 expression in these cells.
Originally described for their antiviral activity, IFNα subtypes
have demonstrated anti-tumor activity in different cancers (16).
The therapeutic effect can be subdivided into those directly affect-
ing tumor cells and those, which require immune mechanisms.
IFNα exerts multiple biological effects, such as induction of apop-
tosis and inhibition of cell growth (17). The ability to enhance
immune recognition of tumor cells by increasing MHC class I
molecule expression resembles the intersection between direct
and indirect effects of IFNα. The latter comprises several effects
on immune competent host cells, e.g., enhancing differentiation
of Th1 T-cell responses, generation, and activation of cytotoxic
T–cells, as well as differentiation of DCs (16). Preclinical stud-
ies suggest that the applied dose determines which anti-tumor
effect is triggered (18). In the adjuvant setting, direct effects on
tumor cells are difficult – if not impossible – to determine, but
the immune modulatory functions of IFNα are clearly evident.
For example, in melanoma patients, the appearance of autoanti-
bodies or clinical manifestations of autoimmunity during therapy
was associated with an improved DMFS (19). Similarly, a therapy-
associated increase of STAT1 activation in PBLs also correlated
with the clinical benefit (20).
It is well established that IFN mediates its effect by STAT signal-
ing (16). For example, the interferon-stimulated response elements
(ISRE) of interferon-stimulated genes bind protein complexes
containing phosphorylated STAT1 and STAT2 (21). Furthermore,
it has been demonstrated that STAT3 expression increased the
sensitivity to type I interferons in otherwise resistant cell lines
(8). STAT3 has also been implicated in the clinical outcome of
IFNα therapy. In a small study with 24 patients, the effect of
IFNα treatment on phosphorylation of tyrosine at position 705
of STAT3 was determined (22). Phosphorylation of tyrosine 705 is
necessary for STAT3 dimerization through phosphotyrosine-SH2
domain, which is a prerequisite for STAT3 transcriptional activity
[reviewed in Ref. (23)]. Notably, STAT3 tyrosine 705 phosphory-
lation status in response to IFNα administration correlated with
DMFS and OS. Since type I IFNs are weak activators of STAT3 (24),
IFNα sensitivity should already be affected by the STAT3 expres-
sion level. Indeed, knockdown of STAT3 enhances IFNαmediated
cell growth inhibition in vitro. These observations suggest that
direct effect of the STAT3 rs4796793 SNP are responsible for the
reported effects on efficacy of IFNα in renal cell carcinoma patients
(7). In a recent report by Kreil et al., the association between the
STAT5B rs6503691 SNP and response of chronic myeloid leukemia
(CML) to IFNαwas demonstrated (25). Interestingly, this SNP was
not related to STAT5A or STAT5B mRNA expression, but to STAT3
mRNA expression, suggesting an association of STAT3 expression
and IFNα efficacy.
Although we did not detect a correlation between the STAT3
rs4796793 genotype and STAT3 mRNA levels, our in vitro results
suggest that the presence of the minor allele increases the sensi-
tivity of melanoma cells toward IFNα. Nevertheless, this in vitro
effect did not translate into a clinical association. In the tested
melanoma cohort receiving adjuvant IFNα therapy, no correla-
tion between the STAT3 rs4796793 genotype and DMFS or OS
was evident. It should be noted that given the number of patients
and the event rate in the IFNα treated patients, a Cox regression
for DMFS achieves 80% power at a 0.05 significance level to detect
a hazard ratio of 1.51. Thus, it is rather unlikely that if the STAT3
rs4796793 SNP has a relevant impact, it would have been missed
because of the size of the analyzed cohort. Consequently, the here
presented data do not support a significant impact of the STAT3
rs4796793 SNP on IFNα efficacy in melanoma patients.
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